Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.01.30.526266Source: DataRank Database

IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer is a research paper published in bioRxiv (Cold Spring Harbor Laboratory) (2023). On theSindex it has a DataRank of 0. It has been cited 4 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access4 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (18 grants)OA: greenTopics (34)IDs (PubMed, OpenAlex)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Patrick Smith ORCID,Juan Carlos Angulo-Lozano ORCID,Daniel Ranti ORCID,Bernard H. Bochner ORCID,John P. Sfakianos ORCID

Live enrichment

PubMed:36778311 OpenAlex:https://openalex.org/W4318761584

National Institutes of Health

Grant: 1K08CA248966-01

Fc-enhanced CD40 agonist antibodies for immune modulation of the tumor microenvironment

National Institutes of Health

Grant: 2P30CA008748-43

MOUSE GENETICS

National Institutes of Health

Grant: 1P50CA221745-01A1

SPORE in Bladder Cancer

National Institutes of Health

Grant: 5R35CA196620-02

Molecular mechanisms of antibody-mediated immunotherapies

National Institutes of Health

Grant: 5UL1TR001866-07

Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational Success

National Institutes of Health

Grant: 5R01CA244327-04

Novel Transgenic Mouse Models Addressing Outstanding Translational Barriers in Antibody-Based Therapeutics

National Institutes of Health

Grant: 5KL2TR001865-10

Institutional Career Development Core

National Institutes of Health

Grant: 1F32CA250147-01

CD40 agonism for the treatment of bladder cancer

National Institutes of Health

Grant: 3P01CA190174-04S1

Immunologic Approaches to Ovarian Cancer

NCATS NIH HHS

Grant: UL1 TR001866

NCI NIH HHS

Grant: P30 CA008748

NCI NIH HHS

Grant: P50 CA221745

NCI NIH HHS

Grant: P01 CA190174

NCI NIH HHS

Grant: R35 CA196620

NCI NIH HHS

Grant: F32 CA250147

NCATS NIH HHS

Grant: KL2 TR001865

NCI NIH HHS

Grant: R01 CA244327

NCI NIH HHS

Grant: K08 CA248966

greenLicense: cc-by-nc-nd

repositoryhttps://www.biorxiv.org/content/biorxiv/early/2023/02/01/2023.01.30.526266.full.pdf

publisherhttps://syndication.highwire.org/content/doi/10.1101/2023.01.30.526266

repositoryhttp://dx.doi.org/10.1101/2023.01.30.526266

repositoryhttps://pubmed.ncbi.nlm.nih.gov/36778311

Fields of Study

Immune Cell Function and InteractionImmunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers0301 basic medicine0303 health sciences03 medical and health sciences

Keywords

Cancer researchCD40Bladder cancerAgonistTumor microenvironmentMedicineImmunologyAntibodyCD8Systemic administrationImmune systemCancerBiologyCytotoxic T cellReceptorInternal medicineIn vivoIn vitroInterleukin-15Urinary Bladder NeoplasmsUrinary BladderHumansAntibodies, MonoclonalBiological SciencesCD40 AntigensCombined Modality TherapyArticleImmunoglobulin Fc Fragments